Loading...
Market
What will be Recursion Pharmaceuticals' market cap by end of 2024?
3
Resolution / Starting Odds
Less than $1 billion • 25%
$1 billion to $5 billion • 25%
$5 billion to $10 billion • 25%
More than $10 billion • 25%
Stock market data from recognized financial platforms (e.g., Nasdaq, Yahoo Finance)
Story
Recursion's First-in-Disease Drug REC-994 Meets Safety Endpoint, Efficacy Mixed in Phase 2 Study
Sep 3, 2024, 12:12 PM
Recursion Pharmaceuticals has announced the Phase 2 data for REC-994, its first-in-disease investigational treatment for symptomatic cerebral cavernous malformation (CCM). The AI-derived drug candidate met its primary endpoint of safety and tolerability in the mid-stage study. However, the efficacy results were mixed, with magnetic resonance imaging-based secondary endpoints showing a trend towards reduced lesion volume but not achieving significant efficacy. While the topline results are positive, they may not fully satisfy investors closely monitoring the AI drug developer.
View original story
Similar markets
Below $2 billion • 25%
$2 billion to $4 billion • 25%
$4 billion to $6 billion • 25%
Above $6 billion • 25%
Below $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
Above $3 billion • 25%
Increase by 10% or more • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant increase • 25%
Below $10 • 25%
$10 to $15 • 25%
$15 to $20 • 25%
Above $20 • 25%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
No increase or decrease • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Increase by more than 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%
Decrease • 25%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%
Yes • 50%
No • 50%
Less than $150 billion • 25%
$150 billion to $170 billion • 25%
$170 billion to $190 billion • 25%
More than $190 billion • 25%